Complement in Neurological Disorders and Emerging Complement-targeted Therapeutics

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2020 Oct 2

PMID 33005040

Citations 149

Authors

Marinos C Dalakas

Harry Alexopoulos

Peter J Spaeth

Affiliations

Soon will be listed here.

Abstract

The complement system consists of a network of plasma and membrane proteins that modulate tissue homeostasis and contribute to immune surveillance by interacting with the innate and adaptive immune systems. Dysregulation, impairment or inadvertent activation of complement components contribute to the pathogenesis of some autoimmune neurological disorders and could even contribute to neurodegenerative diseases. In this Review, we summarize current knowledge about the main functions of the complement pathways and the involvement of complement in neurological disorders. We describe the complex network of complement proteins that target muscle, the neuromuscular junction, peripheral nerves, the spinal cord or the brain and discuss the autoimmune mechanisms of complement-mediated myopathies, myasthenia, peripheral neuropathies, neuromyelitis and other CNS disorders. We also consider the emerging role of complement in some neurodegenerative diseases, such as Alzheimer disease, amyotrophic lateral sclerosis and even schizophrenia. Finally, we provide an overview of the latest complement-targeted immunotherapies including monoclonal antibodies, fusion proteins and peptidomimetics that have been approved, that are undergoing phase I-III clinical trials or that show promise for the treatment of neurological conditions that respond poorly to existing immunotherapies.

Citing Articles

Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen.

Cebulla G, Hai L, Warnken U, Gungor C, Hoffmann D, Korporal-Kuhnke M J Neurol. 2025; 272(4):270.

PMID: 40085221 DOI: 10.1007/s00415-025-12984-7.

Pathogenesis and therapeutic applications of microglia receptors in Alzheimer's disease.

Fu J, Wang R, He J, Liu X, Wang X, Yao J Front Immunol. 2025; 16:1508023.

PMID: 40028337 PMC: 11867950. DOI: 10.3389/fimmu.2025.1508023.

Acetylcholine receptor blocking antibodies in myasthenia gravis: reevaluating their role in disease severity and mechanisms.

Seok H, Eun M Neurol Sci. 2025; .

PMID: 40014227 DOI: 10.1007/s10072-025-08070-5.

Exploring the Effects of Metformin on the Body via the Urine Proteome.

Chen Y, Wang H, Yang M, Shen Z, Gao Y Biomolecules. 2025; 15(2).

PMID: 40001544 PMC: 11853151. DOI: 10.3390/biom15020241.

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report.

Khalil N, Guerra Hernandez C, Farias J, Murray K, Suresh N, Gooch C Case Rep Neurol. 2025; 17(1):25-30.

PMID: 39981032 PMC: 11805545. DOI: 10.1159/000543216.

References

Duchow A, Paul F, Bellmann-Strobl J . Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opin Biol Ther. 2020; 20(9):1061-1072. DOI: 10.1080/14712598.2020.1749259. View

Karbian N, Eshed-Eisenbach Y, Tabib A, Hoizman H, Morgan B, Schueler-Furman O . Molecular pathogenesis of human CD59 deficiency. Neurol Genet. 2018; 4(6):e280. PMC: 6244018. DOI: 10.1212/NXG.0000000000000280. View

Kawamoto M, Murakami Y, Kinoshita T, Kohara N . Recurrent aseptic meningitis with mutations: a novel pathogenesis of recurrent meningitis successfully treated by eculizumab. BMJ Case Rep. 2018; 2018. PMC: 6169622. DOI: 10.1136/bcr-2018-225910. View

Ingram G, Hakobyan S, Robertson N, Morgan B . Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol. 2010; 223(1-2):124-7. DOI: 10.1016/j.jneuroim.2010.03.014. View

Morgan B . Complement in the pathogenesis of Alzheimer's disease. Semin Immunopathol. 2017; 40(1):113-124. PMC: 5794825. DOI: 10.1007/s00281-017-0662-9. View

Kissel J, Mendell J, Rammohan K . Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986; 314(6):329-34. DOI: 10.1056/NEJM198602063140601. View

Harschnitz O, van den Berg L, Johansen L, Jansen M, Kling S, Vieira de Sa R . Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann Neurol. 2016; 80(1):71-88. DOI: 10.1002/ana.24680. View

Zanjani H, Finch C, Kemper C, Atkinson J, McKeel D, Morris J . Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord. 2005; 19(2):55-66. DOI: 10.1097/01.wad.0000165506.60370.94. View

Fitzpatrick A, Mann C, Barry S, Brennan K, Overell J, Willison H . An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011; 16(2):84-91. DOI: 10.1111/j.1529-8027.2011.00328.x. View

10.

Carvajal-Gonzalez A, Leite M, Waters P, Woodhall M, Coutinho E, Balint B . Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014; 137(Pt 8):2178-92. PMC: 4107739. DOI: 10.1093/brain/awu142. View

11.

Mortensen S, Sander B, Jensen R, Pedersen J, Golas M, Thiel S . Models of the complement C1 complex. Proc Natl Acad Sci U S A. 2018; 115(17):E3866. PMC: 5924934. DOI: 10.1073/pnas.1803577115. View

12.

Mohebnasab M, Eriksson O, Persson B, Sandholm K, Mohlin C, Huber-Lang M . Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Front Immunol. 2019; 10:2539. PMC: 6856077. DOI: 10.3389/fimmu.2019.02539. View

13.

Pittock S, Berthele A, Fujihara K, Kim H, Levy M, Palace J . Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7):614-625. DOI: 10.1056/NEJMoa1900866. View

14.

Goodfellow J, Bowes T, Sheikh K, Odaka M, Halstead S, Humphreys P . Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci. 2005; 25(7):1620-8. PMC: 6725939. DOI: 10.1523/JNEUROSCI.4279-04.2005. View

15.

Mastaglio S, Ruggeri A, Risitano A, Angelillo P, Yancopoulou D, Mastellos D . The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215:108450. PMC: 7189192. DOI: 10.1016/j.clim.2020.108450. View

16.

Chen Z, Pellarin R, Fischer L, Sali A, Nilges M, Barlow P . Structure of Complement C3(H2O) Revealed By Quantitative Cross-Linking/Mass Spectrometry And Modeling. Mol Cell Proteomics. 2016; 15(8):2730-43. PMC: 4974347. DOI: 10.1074/mcp.M115.056473. View

17.

Tenner A, Stevens B, Woodruff T . New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol Immunol. 2018; 102:3-13. PMC: 6478444. DOI: 10.1016/j.molimm.2018.06.264. View

18.

Stathopoulos P, Alexopoulos H, Dalakas M . Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 2015; 11(3):143-56. DOI: 10.1038/nrneurol.2014.260. View

19.

Dalakas M . Inflammatory Muscle Diseases. N Engl J Med. 2015; 373(4):393-4. DOI: 10.1056/NEJMc1506827. View

20.

Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K . Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018; 17(6):519-529. DOI: 10.1016/S1474-4422(18)30114-5. View